老虎證券

BRIEF-Pfizer Says LB6V Vaccine Candidate Was Well Tolerated With No Safety Concerns Identified At Time Of Analysis

Reuters
昨天
BRIEF-Pfizer Says LB6V Vaccine Candidate Was Well Tolerated With No Safety Concerns Identified At Time Of Analysis

March 23 (Reuters) - Pfizer Inc PFE.N:

  • PFIZER: LB6V VACCINE CANDIDATE WAS WELL TOLERATED WITH NO SAFETY CONCERNS IDENTIFIED AT TIME OF ANALYSIS

  • PFIZER: CO & VALNEVA ANNOUNCE LYME DISEASE VACCINE CANDIDATE DEMONSTRATES STRONG EFFICACY IN PHASE 3 VALOR TRIAL

  • PFIZER: PLANNING SUBMISSIONS FOR LB6V VACCINE CANDIDATE TO REGULATORY AUTHORITIES

  • PFIZER: VACCINE CANDIDATE LB6V SHOWED MORE THAN 70% EFFICACY IN PREVENTING LYME DISEASE IN PEOPLE AGED FIVE YEARS & ABOVE

Source text: [ID:]

Further company coverage: PFE.N

((Reuters.Briefs@thomsonreuters.com;))

應版權方要求，你需要登入查看該內容

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10